Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures - Takeaways - MDSpire

Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures

  • By

  • Mohammed Nabil Quraishi

  • Jonathan Cheesbrough

  • Peter Rimmer

  • Benjamin H Mullish

  • Naveen Sharma

  • Elena Efstathiou

  • Animesh Acharjee

  • Georgios Gkoutus

  • Arzoo Patel

  • Julian R Marchesi

  • Stephane Camuzeaux

  • Katie Chappell

  • Maria A Valdivia-Garcia

  • James Ferguson

  • Matthew J Brookes

  • Martine Walmsley

  • Amanda E Rossiter

  • Willem van Schaik

  • Ross S McInnes

  • Rachel Cooney

  • Michael Trauner

  • Andrew D Beggs

  • Tariq H Iqbal

  • Palak J Trivedi

  • December 14, 2024

  • 0 min

Share

  • 1

    Oral vancomycin treatment induced clinical remission in 12 of 15 patients with primary sclerosing cholangitis-associated inflammatory bowel disease.

  • 2

    Significant reductions in fecal calprotectin levels were observed after 4 weeks of oral vancomycin treatment.

  • 3

    Treatment with oral vancomycin altered gut microbiota composition, reducing Lachnospiraceae and increasing Enterobacteriaceae.

  • 4

    Metatranscriptomic analysis revealed downregulation of pathways related to short-chain fatty acid metabolism and inflammatory responses.

  • 5

    Colitis activity relapsed after vancomycin withdrawal, indicating the need for ongoing management in PSC-IBD patients.

Original Source(s)

Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic Signatures

  • by Mohammed Nabil Quraishi, Jonathan Cheesbrough, Peter Rimmer, Benjamin H Mullish, Naveen Sharma, Elena Efstathiou, Animesh Acharjee, Georgios Gkoutus, Arzoo Patel, Julian R Marchesi, Stephane Camuzeaux, Katie Chappell, Maria A Valdivia-Garcia, James Ferguson, Matthew J Brookes, Martine Walmsley, Amanda E Rossiter, Willem van Schaik, Ross S McInnes, Rachel Cooney, Michael Trauner, Andrew D Beggs, Tariq H Iqbal, Palak J Trivedi

  • December 14, 2024

Related Content

Mortality trends from colorectal pathologies in the United States (1999–2020): a retrospective cohort study using CDC WONDER

Progression of Coronary Calcium Detected on Routine Chest CT Enhances Cardiovascular Risk Assessment in Individuals with Inflammatory Bowel Disease: Findings from a Multicenter Study

Incidence of Clostridium difficile infection and enteric pathogens in children with inflammatory bowel disease presenting with disease exacerbation